Rad9A is required for G2 decatenation checkpoint and to prevent endoreduplication in response to topoisomerase II inhibition.
Greer Card
Deborah A
DA
Cancer Research Institute, Division of Cancer Biology and Genetics, Queen's University, Kingston, Ontario K7L 3N6, Canada; Departments of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario K7L 3N6, Canada.
Sierant
Megan L
ML
Cancer Research Institute, Division of Cancer Biology and Genetics, Queen's University, Kingston, Ontario K7L 3N6, Canada; Departments of Biochemistry, Queen's University, Kingston, Ontario K7L 3N6, Canada.
Davey
Scott
S
Cancer Research Institute, Division of Cancer Biology and Genetics, Queen's University, Kingston, Ontario K7L 3N6, Canada; Departments of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario K7L 3N6, Canada; Departments of Biochemistry, Queen's University, Kingston, Ontario K7L 3N6, Canada; Departments of Oncology, Queen's University, Kingston, Ontario K7L 3N6, Canada. Electronic address: sd13@queensu.ca.
D000818:Animals; D018797:Cell Cycle Proteins / Q000378:metabolism / Q000502:physiology*; D064447:Checkpoint Kinase 2; D054659:Diketopiperazines; D053595:Embryonic Stem Cells / Q000166:cytology; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D016195:G2 Phase; D006367:HeLa Cells; D006801:Humans; D051379:Mice; D010766:Phosphorylation; D010879:Piperazines / Q000494:pharmacology; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism; D059005:Topoisomerase II Inhibitors
D018797:Cell Cycle Proteins; D054659:Diketopiperazines; D004791:Enzyme Inhibitors; D010879:Piperazines; D059005:Topoisomerase II Inhibitors; C069930:rad9 protein; C070899:4,4'-(1,2-dimethyl-1,2-ethanediyl)bis-2,6-piperazinedione; D064447:Checkpoint Kinase 2; C578634:CHEK2 protein, human; C578633:Chek2 protein, mouse; D017346:Protein Serine-Threonine Kinases